Abstract PO3-04-13: SUMIT-ELA: Phase 1b/2 Combination of Cyclin-Dependent Kinase 7 Inhibitor (cdk7i) Samuraciclib and Selective Estrogen Receptor Degrader (SERD) Elacestrant in Advanced Hormone Receptor Positive (HR+) Breast Cancer after CDK4/6i